The HCT 116 AXL KO Tet-inducible cell line enables further investigation into the target as a prognostic biomarker and therapeutic target.
| Inventor | Institute |
|---|---|
| Sandra Van Schaeybroeck | Queen's University Belfast |
| SKU: | 153206 |
|---|---|
| Product description: | Receptor tyrosine kinase (RTK) screens identifed AXL as a protein which underpins the migratory/invasive phenotype in colorectal cancer (CRC) (Dunne et al., 2014). AXL was shown to be a poor prognostic marker and an important mediator of cell migration/invasiveness. The HCT 116 AXL KO Tet-inducible cell line enables further investigation into the target as a prognostic biomarker and therapeutic target. |
| Conditional: | Yes |
| Conditional description: | Conditional knockdown of endogenous AXL expression upon treatment with Tetracycline |
| Production details: | HCT 116 cells were transfected with pTRIPZ plasmid encoding Tet-inducible shRNA against AXL. Stably transfected cells were selected, maintained in mediumsupplemented with 0.5ÄÂÄ?g/mL puromycin and induced with 2ÄÂÄ?g/ml doxycycline. |
| Cellosaurus ID: | CVCL_HG04 |
| Parental cell line: | HCT 116 |
| Disease: | Cancer |
| Cat. #: | 153206 |
|---|---|
| Provenance and Ownership: | The HCT 116 AXL KO Tet-inducible Cell Line is owned by Cancer Research UK. CancerTools supplies the HCT 116 AXL KO Tet-inducible Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing HCT 116 AXL KO Tet-inducible Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Cancer types: | Colorectal cancer |
| Research Fields: | Cancer;Cell biology;Drug development |
| Organism: | Human |
| Tissue: | Colon |
| Model: | Knock-Out |
| Growth properties: | Invasion, migration |
| Cancer Types In Detail: | Colorectal |
| Format: | Frozen |
|---|---|
| Storage conditions: | Liquid Nitrogen |
| Shipping conditions: | Dry ice |
| Growth medium: | McCoy’s 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 ?g/ml streptomycin |
| Recommended controls: | HCT 116 parental line |
| Mycoplasma free: | Yes |
| Biosafety level: | 1 |
| References: |
Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546. AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.